Access TOC
Download Data
December 2024
The global biomaterials market size was estimated at US$ 178.16 billion in 2023 and is projected to grow US$ 761.23 billion by 2033, rising at a compound annual growth rate (CAGR) of 15.63% from 2024 to 2033. It is anticipated that the increasing prevalence of musculoskeletal and chronic skeletal disorders would increase demand for biomaterial-based implants.
Unlock Infinite Advantages: Subscribe to Annual Membership
The biomaterials market deals with the production and distribution of biomaterials. Biomaterials may be made from a variety of materials, including metals, glass, plastic, ceramics, and even biological cells and tissue. They can be redesigned to become textiles, films, coatings, molded or machined components, fibers, films, and foams for application in biomedical devices and goods. Contact lenses, dental implants, hip replacements, and heart valves are a few examples of them. Many of them are biodegradable, and some are even bio-absorbable, which means that after serving a purpose, the body gradually gets rid of them. Today's medicine heavily relies on biomaterials. helping people recover from illness or injuries and restoring their function. Biomaterials can be manufactured or natural, and they are used in medicine to replace, improve, or maintain damaged tissue or biological functions.
| Company Name | Jellagen |
| Headquarters | United Kingdom |
| Pipeline | In November 2023, the potential for jellyfish collagen to serve as the basis for a variety of novel medical applications and to assist novel biological research has been demonstrated by recent research conducted by the National Physical Laboratory (NPL) and the biotechnology business Jellagen Ltd. In order to help NPL develop jellyfish collagen into a high-quality biomaterial product for use in medical applications, Jellagen cooperated with the latter company. In response to this quest, Jellagen created a ground-breaking biomaterial based on an ECM matrix of collagen from jellyfish that is over 500 million years old and has been repeatedly replicated in various living forms for millions of years. |
| Company Name | MycoWorks |
| Headquarters | California, U.S. |
| Pipeline | In January 2024, the pioneer in biotechnology, MycoWorks, has announced that it has harvested more than a thousand sheets of its revolutionary luxury biomaterial that can replace leather on a commercial scale. By now, the plant has produced products of a higher caliber than its pilot plant in California. |
Chronic wound is a common issue that arises post surgeries. Increasing number of surgeries due to older population, accidents and chronic diseases has increased the occurrence of chronic wounds. Biomaterials are employed to assist the body during wound healing by encouraging cell migration and development as well as the creation of new tissue. The mechanical characteristics of biomaterials employed in wound healing are critical for their ability to support these processes. Appropriate mechanical strength, flexibility, porosity, structure, biodegradability, and biocompatibility are characteristics of biomaterials for skin regeneration. Biomaterials for wound healing might be synthetic, natural, or a mix of the two. Gelatin, fibrinogen, silk, collagen, and silk are examples of natural biomaterials. Biomaterials have proven to be highly promising in improving skin wound-healing results, namely in terms of quickening the healing process and decreasing scarring and wound contracture.
For instance,
A biomaterial's biocompatibility is a crucial characteristic that sets it apart from other materials. This reaction of the host to biomaterials is known as the appropriate host response. Since biomaterial biocompatibility plays a major role in restricting device lifetime and functioning, the research of biocompatibility is increasingly multidisciplinary. A dynamic, continuous process may be used to represent the multifaceted nature of biocompatibility. There are still disagreements regarding certain materials' biocompatibility. Assessing a material's biocompatibility is a highly intricate process. It is predicated on three exam levels. Developing biomaterials with high biocompatibility that can optimize medical treatment outcomes is a problem for biomaterials scientists.
It is possible to recreate some of the complexity of natural biomaterials in synthetic systems through the use of supramolecular biomaterials based on noncovalent interactions. Supramolecular biomaterials, which are molecular complexes that function beyond the capabilities of individual molecules, possess the ability to feel and react, rendering them perfect materials for the treatment of illnesses or injuries. The creation of supramolecular biomaterials that replicate natural biological signaling or that may be switched on or off in response to physiological stimuli is being investigated by researchers.
By product, the metallic segment held the largest market share in 2023. The most common class of materials found in extremely tension-loaded implants are metallic biomaterials. They are designed systems intended to give biological tissues intrinsic support. They are widely utilized in orthopedic fixations, dental implants, stents, spinal fixation devices, joint replacements (artificial joints, such as a hip joint), and nails. Furthermore, a lot of attention has been drawn to their application in the formation of neurovascular implants (aneurysm clips) and cardiovascular devices (artificial heart valves, blood conduits, and other parts of cardiac assist devices, vascular stents). Metallic biomaterials can be used in the repair of soft tissues like blood vessels as well as in substitution of failing hard tissue.
By product, the natural segment is estimated to show lucrative growth during the forecast period. The diverse range of distinct and intricate elements, microstructures, and physiological qualities may be observed in natural biomaterials that are sourced from renewable resources, including plants, animals, and microbes. These substances provide a biological scaffold that can promote the adhesion and proliferation of cells performing a wide range of tasks in their natural environment. The perfect template for creating live implants for particular uses in regenerative medicine and tissue engineering can thus be found in natural biomaterials that have been repopulated with autologous or genetically modified cells. Because of their form and mechanical flexibility, microstructure interconnectivity, and intrinsic bioactivity, which resembles the original ECM, they are therefore an excellent alternative for biomimetic TE scaffolds.
By application, the orthopedic segment held the dominant share of the biomaterials market in 2023. Orthopedics is one of the medical specialties that has advanced and used biomaterials to great effect. These resources are used to treat injuries and illnesses of the musculoskeletal system. Orthopedic biomaterials are incorporated into the human body to perform a variety of biological tasks, including directing bone regeneration and replacing or repairing tissues including bone, cartilage, ligaments, and tendons.
By application, the plastic surgery segment is estimated to grow at the fastest CAGR during the forecast period. Radiology and oral surgery, body contouring and liposuction, maxillofacial surgery, breast surgery, and face cosmetic operations are all included in the vast area of plastic surgery. Biomaterials have become widely employed because to their improved biocompatibility and biodegradability, as a result of plastic surgery regulations for biological safety of materials. Biomaterials are being employed in plastic surgery for a wide range of purposes, and there are many different kinds of them. Furthermore, the creation of microporous, macroscopically more precise, and individualized bio-scaffolding materials has advanced recently with the growth of three-dimensional printing technology, which is anticipated to lead to new developments in the field of biomaterials.
By region, North America dominated the biomaterials market in 2023. A combination of strict regulatory frameworks that promote innovation and supportive government policies for R&D projects drive the market. It also helps that the area is home to many significant market participants, which creates a strong environment for investment and cooperation. Due to this favorable climate, tissue engineering, regenerative medicine, and medical device innovation have all advanced significantly in North America, placing the continent at the forefront of biomaterial innovation.
Another factor that contribute to the growth of the biomaterials market in North America is due to the increased number of health conditions that require biomaterials for treatment. An international public health concern, bone fractures can be caused by trauma, fractures, age and autoimmune disorders, tumor removal, and surgical complications. According to reports, there are around 15 million bone fractures in the U.S, annually. This number comprises 1.6 million hospital admissions for traumatic fractures, 2 million osteoporotic fractures, 500,000 knee replacements, and 350,000 hip replacements. The total cost of bone defects to the healthcare sector is estimated to be over 60 billion dollars, and an estimated 1.6 million bone transplants are needed each year. Because of the growing baby boomer generation and increased life expectancy, these figures are predicted to climb. The development of innovative biomaterials is therefore desperately needed to improve the therapy choices for bone fracture healing and regeneration.
By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. Asia Pacific’s biomaterials market is growing rapidly due to factors such as growing middle class, rising healthcare expenses, and improving understanding of biomaterial uses. China and India are rising to prominence in the region as producers of biomaterials. India, China, and South Korea are majorly contributing due to the rise in usage of orthopedic, dental and cardiovascular biomaterials.
The regulatory science action plan (RSAP) has been adopted by China's National Medical Products Administration (NMPA). Released and put into effect in 2022, the RSAP contains guidelines for novel materials and products, including the one that introduces the idea of PMBs on pure titanium with great strength and toughness.
In India, biotechnologists, chemists, physicists, biologists, engineers, and medical professionals are becoming more and more interested in biomaterials and their uses in artificial organs, medical devices, tissue engineering, nanotechnology, and drug delivery.
By Product
By Application
By Region
December 2024
December 2024
December 2024
December 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts